Sanofi, MyoKardia in cardiomyopathy deal

Sanofi (Euronext:SAN; NYSE:SNY) and MyoKardia Inc. (San Francisco, Calif.) partnered to develop targeted therapeutics for hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM).

MyoKardia will develop two HCM programs through early human efficacy studies, after which the companies will share development costs equally. Sanofi received ex-U.S rights to commercialize the HCM products, and MyoKardia retains commercialization rights in the U.S. ...